AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6227456 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of the laparoscopic Trocar without the use of carbon dioxide gas
Number of subjects: 914
Study 30832590 — intervention group
Group type: EXPERIMENTAL
Intervention: CVS as a video stylet (CVS‐V)
Number of subjects: 150
Study 30832590 — intervention group
Group type: EXPERIMENTAL
Intervention: CVS as a lightwand (CVS‐L)
Number of subjects: 150
Study 30832590 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope (DL)
Number of subjects: 150
Study 30086747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-period six month recall
Number of subjects: 2372
Study 30086747 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based recall
Number of subjects: 2372
Study 30086747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-period twenty-four month recall
Number of subjects: 2372
Study 26354593 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-with-movement intervention, developed by a registered music therapist, taught to staff over five weekly 1.5 h sessions.
Number of subjects: 0
Study 24771728 — intervention group
Group type: COMPARATOR
Intervention: Steel wire closure
Number of subjects: 200
Study 24771728 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester suture closure
Number of subjects: 200
Study 22395920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine intestinal alkaline phosphatase (bIAP) administered as an intravenous bolus followed by continuous infusion for 36 hours.
Number of subjects: 63
Study 22395920 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as an intravenous bolus followed by continuous infusion for 36 hours.
Number of subjects: 63
Study 20617218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-socket attachment
Number of subjects: 18
Study 20617218 — intervention group
Group type: COMPARATOR
Intervention: Bar-clip attachment
Number of subjects: 18
Study 18520981 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (10 g/d)
Number of subjects: 0
Study 18520981 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/d)
Number of subjects: 0
Study 18520981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18520981 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 0
Study 18520981 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 0
Study 18520981 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine and Minocycline
Number of subjects: 0
Study 15942183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential antiarrhythmic therapy (propafenone, sotalol, disopyramide) followed by amiodarone if needed
Number of subjects: 128
Study 15942183 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone as the third antiarrhythmic agent
Number of subjects: 128
Study 12374449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ability (HA) group
Number of subjects: 60
Study 12374449 — intervention group
Group type: COMPARATOR
Intervention: Lower ability (LA) group
Number of subjects: 60
Study 9931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day)
Number of subjects: 12
Study 9931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day)
Number of subjects: 12
Study 9931196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7791815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (7.5 mg daily for two years)
Number of subjects: 128
Study 7791815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 2505689 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time limited to 0.5 seconds (Group A)
Number of subjects: 40
Study 2505689 — intervention group
Group type: COMPARATOR
Intervention: Ventilator rate reduced with inspiratory time reaching 1.0 seconds (Group B)
Number of subjects: 40
Study 30951609 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Counseling
Number of subjects: 46
Study 30951609 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Activation
Number of subjects: 46
Study 28557178 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (imipramine, venlafaxine, escitalopram)
Number of subjects: 244
Study 28557178 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants (pregabalin, oxcarbazepine)
Number of subjects: 244
Study 28557178 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 244
Study 28557178 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants
Number of subjects: 244
Study 26262777 — intervention group
Group type: EXPERIMENTAL
Intervention: dolutegravir + abacavir/lamivudine
Number of subjects: 833
Study 26262777 — intervention group
Group type: COMPARATOR
Intervention: efavirenz/tenofovir/emtricitabine
Number of subjects: 833
Study 23602612 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent variable approach for modeling longitudinal and dropout data
Number of subjects: 0
Study 23602612 — intervention group
Group type: COMPARATOR
Intervention: Traditional analyses using time-to-event approach
Number of subjects: 0
Study 22083060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free antimicrobial mouth rinse containing cetylpyridinium chloride
Number of subjects: 226
Study 22083060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mouth rinse)
Number of subjects: 226
Study 18942013 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about a happy event once a week and noting happy events each day for four weeks, receiving small presents after writing.
Number of subjects: 58
Study 18942013 — intervention group
Group type: COMPARATOR
Intervention: Writing about and noting trivial neutral events, no small presents.
Number of subjects: 58
Study 16382116 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions for facilitating transition to survivorship
Number of subjects: 558
Study 14576100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g three times a day)
Number of subjects: 281
Study 14576100 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500 mg four times a day)
Number of subjects: 281
Study 14576100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 281
Study 14576100 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 281
Study 11113068 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg rhuIL-10
Number of subjects: 95
Study 11113068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 8956393 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream for a minimum of 30 minutes
Number of subjects: 41
Study 8956393 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration with 3 mL of 1% lidocaine
Number of subjects: 41
Study 1555269 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 3339
Study 1555269 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative strategy
Number of subjects: 3339
Study 1555269 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 3339
Study 1555269 — intervention group
Group type: EXPERIMENTAL
Intervention: Not current smoker
Number of subjects: 3339
Study 4015742 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen (200 mg/ml) as i.v. bolus injections
Number of subjects: 12
Study 4015742 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen (200 mg/ml) as infusions
Number of subjects: 12
Study 4015742 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen (200 mg/ml) as i.v. bolus injections and infusions
Number of subjects: 12
Study 29381588 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation group (4 sessions of 15 minutes each, 3 self-directed, 1 with feedback)
Number of subjects: 27
Study 29381588 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation group
Number of subjects: 27
Study 29381588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 27683839 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based weight management and healthy lifestyle intervention
Number of subjects: 0
Study 27683839 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24447085 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7041_C allele (haplotype GC1s)
Number of subjects: 198
Study 24447085 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1f haplotype
Number of subjects: 198
Study 22651863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresynchronization implantable cardioverter-defibrillator (ICD)
Number of subjects: 1191
Study 20134408 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 5 mg for 3 days then OLZ 10 mg for 12 days
Number of subjects: 30
Study 20134408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 30
Study 18800994 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat trial for high responders (HR)
Number of subjects: 37
Study 18800994 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat trial for low responders (LR)
Number of subjects: 37
Study 18800994 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall plaque accumulation and bleeding index
Number of subjects: 37
Study 18800994 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival index
Number of subjects: 37
Study 16410889 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination
Number of subjects: 1433
Study 16410889 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group: blood donor candidates)
Number of subjects: 1433
Study 16410889 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group: unvaccinated HCW)
Number of subjects: 1433
Study 16410889 — intervention group
Group type: EXPERIMENTAL
Intervention: Full set of HBV vaccines
Number of subjects: 1433
Study 12120775 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (FRC) with thickness of 0.5 mm, 1 mm, or 2 mm as a gingival increment
Number of subjects: 60
Study 12120775 — intervention group
Group type: COMPARATOR
Intervention: Control group using hybrid resin composite for both gingival and occlusal increments
Number of subjects: 60
Study 11185684 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol-270 (20 ml)
Number of subjects: 0
Study 11185684 — intervention group
Group type: COMPARATOR
Intervention: Iopentol-150 (20 ml)
Number of subjects: 0
Study 7733025 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta formula (26% palmitic acid, esterified predominantly to the sn‐2 position)
Number of subjects: 12
Study 7733025 — intervention group
Group type: COMPARATOR
Intervention: Alpha formula (palmitate mainly at the sn‐1,3 positions)
Number of subjects: 12
Study 2291870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 9
Study 2291870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6990473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephazolin‐cephalexin (37 patients)
Number of subjects: 79
Study 6990473 — intervention group
Group type: COMPARATOR
Intervention: Methenamine hippurate (42 patients)
Number of subjects: 79
Study 30372375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisexual victim
Number of subjects: 0
Study 30372375 — intervention group
Group type: COMPARATOR
Intervention: Straight victim
Number of subjects: 0
Study 30372375 — intervention group
Group type: COMPARATOR
Intervention: Lesbian victim
Number of subjects: 0
Study 30372375 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 0
Study 30372375 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 0
Study 30691508 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned early delivery (initiation of delivery within 48 h of randomisation)
Number of subjects: 0
Study 30691508 — intervention group
Group type: COMPARATOR
Intervention: Usual care (expectant management)
Number of subjects: 0
Study 28596452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidomain intensive vascular care
Number of subjects: 126
Study 28596452 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 126
Study 25863003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-activation positive mood induction
Number of subjects: 106
Study 25863003 — intervention group
Group type: COMPARATOR
Intervention: Low-activation positive mood induction
Number of subjects: 106
Study 25863003 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood condition
Number of subjects: 106
Study 23480315 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 821
Study 23480315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 821
Study 23480315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-SR
Number of subjects: 821
Study 21425736 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST Model
Number of subjects: 135
Study 21425736 — intervention group
Group type: COMPARATOR
Intervention: Matrix Model
Number of subjects: 135
Study 19590019 — intervention group
Group type: EXPERIMENTAL
Intervention: Active corticosteroid inhaler (quadrupling the dose)
Number of subjects: 403
Study 19590019 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler (no change in corticosteroid dose)
Number of subjects: 403
Study 15841498 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with cruciferous vegetables (broccoli)
Number of subjects: 38
Study 15841498 — intervention group
Group type: COMPARATOR
Intervention: Basal diet devoid of fruits and vegetables
Number of subjects: 38
Study 11870117 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg orally three times a day for 4-6 weeks
Number of subjects: 34
Study 11870117 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 34
Study 10411763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 midazolam (n=100)
Number of subjects: 200
Study 10411763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg.kg‐1 midazolam (n=100)
Number of subjects: 200
Study 10411763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ethyl chloride spray
Number of subjects: 200
Study 10411763 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg.kg‐1 midazolam
Number of subjects: 200
Study 10411763 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg.kg‐1 midazolam
Number of subjects: 200
Study 7671027 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric pressures at the tongue blade site for younger subjects
Number of subjects: 25
Study 7671027 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak swallowing pressures
Number of subjects: 25
Study 7671027 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference scores of maximum isometric to swallowing pressures at the tongue blade
Number of subjects: 25
Study 7671027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral atrophy incidence
Number of subjects: 25
Study 7671027 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of periventricular white matter lesions
Number of subjects: 25
Study 2160379 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulphate cream (0.17 mg/g trimethoprim and 10,000 IU/g polymyxin B sulphate)
Number of subjects: 64
Study 2160379 — intervention group
Group type: COMPARATOR
Intervention: Fusidic acid cream (20 mg/g)
Number of subjects: 64
Study 6107292 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 5
Study 6107292 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturate
Number of subjects: 5
Study 6107292 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 5
Study 6107292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6107292 — intervention group
Group type: COMPARATOR
Intervention: No capsule
Number of subjects: 5
Study 30916230 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote nursing monitoring through telephone calls and conventional monitoring
Number of subjects: 101
Study 30916230 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 101
Study 28233585 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust-conveying communication style
Number of subjects: 97
Study 28233585 — intervention group
Group type: COMPARATOR
Intervention: Standard communication style
Number of subjects: 97
Study 25369277 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (600 mg) daily for 11 days
Number of subjects: 32
Study 25369277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24106864 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive supervised training program
Number of subjects: 54
Study 24106864 — intervention group
Group type: EXPERIMENTAL
Intervention: Short version ('3 times 3') home-based training
Number of subjects: 54
Study 24106864 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting group)
Number of subjects: 54
Study 21859489 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary biopsychosocial educational group intervention (MBEGI)
Number of subjects: 932
Study 21859489 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 932
Study 18834816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarming to a nasopharyngeal temperature of 37 degrees C (Group A)
Number of subjects: 80
Study 18834816 — intervention group
Group type: COMPARATOR
Intervention: Rewarming to a nasopharyngeal temperature of 33 degrees C (Group B)
Number of subjects: 80
Study 17720074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with combined primary posterior continuous curvilinear capsulorhexis (PPCCC) and posterior optic buttonholing (POBH)
Number of subjects: 50
Study 17720074 — intervention group
Group type: COMPARATOR
Intervention: Conventional cataract surgery with in-the-bag IOL implantation
Number of subjects: 50
Study 17720074 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of IOP-lowering drops
Number of subjects: 50
Study 14506077 — intervention group
Group type: EXPERIMENTAL
Intervention: GLU (6.4% carbohydrate beverage)
Number of subjects: 7
Study 14506077 — intervention group
Group type: COMPARATOR
Intervention: CON (sweet placebo beverage)
Number of subjects: 7
Study 11226791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 0.25% (0.4 mL)
Number of subjects: 66
Study 11226791 — intervention group
Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS) (control)
Number of subjects: 66
Study 11226791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 0.25%
Number of subjects: 66
Study 9714026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Balance Index (MBI) for patients with nPCR <0.8
Number of subjects: 2
Study 9714026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Balance Index (MBI) for patients with nPCR >0.8
Number of subjects: 2
Study 9714026 — intervention group
Group type: EXPERIMENTAL
Intervention: Kt/V for patients with nPCR <0.8
Number of subjects: 2
Study 9714026 — intervention group
Group type: EXPERIMENTAL
Intervention: Kt/V for patients with nPCR >0.8
Number of subjects: 2
Study 9714026 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Kt/V between both groups
Number of subjects: 2
Study 8029191 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid 3 times per week
Number of subjects: 30
Study 8029191 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg folic acid 3 times per week
Number of subjects: 30
Study 8029191 — intervention group
Group type: COMPARATOR
Intervention: 0 mg folic acid 3 times per week (Control)
Number of subjects: 30
Study 2645345 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6% hypertonic saline (HS)
Number of subjects: 11
Study 2645345 — intervention group
Group type: EXPERIMENTAL
Intervention: Meth challenge (Meth1)
Number of subjects: 11
Study 2645345 — intervention group
Group type: EXPERIMENTAL
Intervention: HS challenge followed by Meth challenge (Meth2)
Number of subjects: 11
Study 2645345 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HS challenge
Number of subjects: 11
Study 4552464 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 40
Study 4552464 — intervention group
Group type: COMPARATOR
Intervention: Dummy tablets (Control)
Number of subjects: 40
Study 29924701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Exercise (SIE) - 4 × 30 s sprints separated by 4.5 min of active recovery
Number of subjects: 16
Study 29924701 — intervention group
Group type: COMPARATOR
Intervention: Continuous Exercise (CE) - 20 min at 65% peak power output
Number of subjects: 16
Study 29924701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SIE and CE
Number of subjects: 16
Study 28711457 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-feeding technique
Number of subjects: 53
Study 28711457 — intervention group
Group type: COMPARATOR
Intervention: Cup feeding method
Number of subjects: 53
Study 26179754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg once-weekly
Number of subjects: 361
Study 26179754 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine once-daily
Number of subjects: 361
Study 23334470 — intervention group
Group type: EXPERIMENTAL
Intervention: minimally invasive percutaneous antegrade ureterolithotripsy (mini-PCNL)
Number of subjects: 59
Study 23334470 — intervention group
Group type: COMPARATOR
Intervention: retrograde ureterolithotripsy (URSL)
Number of subjects: 59
Study 21196806 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 57
Study 21196806 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 57
Study 21196806 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 57
Study 18474884 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for communicating absolute cardiovascular disease risk and shared decision making, provided to 550 patients through 44 physicians attending 2 CME sessions.
Number of subjects: 1132
Study 18474884 — intervention group
Group type: COMPARATOR
Intervention: Control group received 1 CME session on an alternative topic, involving 582 patients.
Number of subjects: 1132
Study 15738298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical decongestant and external dilator strip
Number of subjects: 10